52 Week Range
As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Redx Pharma Signs Out Licensing Agreement With AstraZeneca
Astrazeneca Plc Prices $3 Bln Bond Issue
Wockhardt Intends To Supply 30 Mln Fill-&-Finish COVID-19 Vaccine Doses To AstraZeneca
AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.
Biotechnology & Drugs
1 Francis Crick Avenue
Independent Non-Executive Chairman of the Board
Chief Executive Officer, Executive Director
Chief Financial Officer, Executive Director
Executive Vice President - Sustainability, Chief Compliance Officer
Executive Vice President - Human Resources
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Argentina and Mexico will produce the AstraZeneca COVID-19 vaccine for most of Latin America, Argentine President Alberto Fernandez said on Wednesday after a meeting with company executives involved in the project.
Brazilian billionaire Jorge Lemann's foundation and other business interests will fund the building of factory to produce the COVID-19 vaccine being developed by Oxford University and pharmaceutical company AstraZeneca PLC <AZN.L>.
London's FTSE 100 closed flat on Friday as a commodity-linked slump offset gains spurred by some upbeat earnings and AstraZeneca, while an index of more domestically-focused stocks rose as hopes grew of a trade deal with the European Union.
Japan plans to buy AstraZeneca Plc's experimental COVID-19 vaccine and fund a local company to manufacture Novavax's vaccine candidate, ramping up its stockpile plan as it battles surging infections.
AstraZeneca said on Friday JCR Pharma will help make a portion of its potential COVID-19 vaccine in Japan and it will import shots as part of its deal to supply the Asian nation with up 120 million doses from early 2021.
Japan has agreed to acquire 120 million doses of AstraZeneca Plc's experimental COVID-19 vaccine if it is successfully developed, the health minister said on Friday.
The Japanese government will soon agree a supply deal for more than 100 million doses of a coronavirus vaccine being developed by AstraZeneca Plc <AZN.L>, Kyodo news agency reported on Friday.
AstraZeneca signed its first COVID-19 vaccine supply deal with a Chinese company, Kangtai Bio, on Thursday, opening up distribution to one of the world's most populous countries.
Shenzhen Kangtai Biological Products will produce AstraZeneca Plc's potential COVID-19 vaccine in mainland China, the British drugmaker said on Thursday, its first deal to supply one of the world's most populous countries.
AstraZeneca PLC has signed an exclusive framework agreement with China's Shenzhen Kangtai Biological Products to supply its COVID-19 vaccine candidate in mainland China, the British pharmaceutical giant said on Thursday.
Indian drugmaker Wockhardt Ltd will supply millions of doses of multiple COVID-19 vaccines, including that being developed by AstraZeneca and Oxford University, under a deal with the UK government announced on Monday.
AstraZeneca has been granted protection from future product liability claims related to its COVID-19 vaccine hopeful by most of the countries with which it has struck supply agreements, a senior executive told Reuters.
Britain's AstraZeneca <AZN.L> said on Thursday that good data was coming in so far on its vaccine for COVID-19, already in large-scale human trials and widely seen as the front-runner in the race for a shot against the novel coronavirus.
AstraZeneca has been granted protection from future product liability claims related to its COVID-19 vaccine hopeful by most of the countries it has so far struck supply agreements with, a senior executive told Reuters.
* ASTRAZENECA SAYS NEW LAUNCHES FOR CALQUENCE AND ENHERTU ARE SHOWING GOOD PROGRESS - MEDIA CALL
Gloomy quarterly results from Lloyds Bank and a clutch of other companies led the FTSE 100 lower on Thursday, while AstraZeneca rose after topping analysts' expectations on the back of strong drug sales during coronavirus-driven lockdowns.
Drugmaker AstraZeneca topped second-quarter sales and profit expectations on Thursday and stood by its 2020 forecasts, helped by strong sales in lockdowns of a diverse line-up, which now includes a potential coronavirus vaccine.
AstraZeneca's <AZN.L> diabetes treatment has shown promise in a late-stage trial to help to slow chronic kidney disease, putting it on track for possible expanded approvals ahead of rival drugs.
The U.S. Food and Drug Administration approved AstraZeneca's drug to treat patients with a form of lung disease, the British drugmaker said on Friday.
AstraZeneca's <AZN.L> experimental COVID-19 vaccine was safe and produced an immune response in early-stage clinical trials in healthy volunteers, data showed on Monday.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.